Logo

AstraZeneca Signs an Agreement with Catalent to Manufacture AZD1222 for COVID-19

Share this

AstraZeneca Signs an Agreement with Catalent to Manufacture AZD1222 for COVID-19

Shots:

  • Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca at its manufacturing facility in Italy and prepare for large-scale commercial supply of AZD1222
  • The agreement ramps up the production of AZD1222 and will prepare the facility to enable round-the-clock manufacturing schedules and supply hundreds of millions of doses of AZD1222 from Aug’2020 to Mar’2022
  • The collaboration allows AstraZeneca to meet the global target of supplying 2B doses of its potential COVID-19 vaccine. Catalent’s 28-000 square-meter facility in Anagni offers extensive capabilities in aseptic liquid filling for biologics and sterile products across multiple vial sizes

Click here to read full press release/ article 

Ref: Catalent | Image: Catalent


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions